ClinicalTrials.gg
RecruitingNCT05651724GRIPonMASHUpdated Aug 1, 2024

Global Research Initiative for Patients Screening on MASH

An observational study in MASH, MASLD and MASH With Fibrosis, sponsored by Julius Clinical. Recruiting at 13 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Julius Clinical · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Liver Cirrhosis with a site in Belgium — 11 open to participants now, 13 under way, 2 of them phase 3. Liver Cirrhosis · Belgium.

Planned enrollment
Largest of 17
10,000 · median 450
Started
2023
the only one that year
Observational
17 of 41
8 open now
Primary completion
2031-03
later than 11 of 12 live
Registered
33rd of 41
by date

Among the 41 studies in Liver Cirrhosis with a site in Belgium, this one has the largest planned enrollment of the 17 observational ones that give a count, is the only one that started in 2023, is one of 17 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 33rd registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

11 of the 41 studies in Liver Cirrhosis with a site in Belgium are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Liver Cirrhosis with a site in Belgium, or all of them as a file.
02

Study summary

GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) in primary care centres and clinics in 10 European countries.

Read the detailed description

GRIPonMASH is an observational study in which 10.000 high risk patients (type 2 diabetes mellitus, metabolic syndrome, obesity or arterial hypertension) in 10 different European countries will be screened for the presence of MASLD, liver fibrosis and (at-rsik) MASH using at least two non-invasive tests (FIB-4 and FibroScan). Additional published and exploratory non-invasive test will also be investigated. Blood samples and liver biopsy material will be collected. Genomic, proteomic, metabolomic, lipidomic and fluxomic studies will be applied to gain a better understanding of the pathophysiology of MASLD and to identify (bio)markers that will help to detect patients at-risk. The predictive value of FIB-4 in relation to FibroScan results and liver biopsy will be analysed. Long-term follow-up of 5 years in all participants will provide insight into the natural history of the disease.

03

Conditions studied

  • MASH
  • MASLD
  • MASH With Fibrosis
  • Fibrosis, Liver
  • Steatosis of Liver
  • Type 2 Diabetes
  • Obesity
  • Metabolic Syndrome
  • Arterial Hypertension

Keywords

  • MASLD
  • MASH
  • Screening
  • Patient care pathway
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male and female patients aged 18-75 years with a current or prior diagnosis of at least one of the following four conditions: type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension. Subjects who meet the inclusion and exclusion criteria will be enrolled at primary care centers in one of the 10 countries.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed subjects should fulfil criteria for diagnosis of type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension, following the study definitions.
  • Subjects that are currently being treated for type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension, should have had a prior diagnosis based on study definitions.

Study definitions:

Type 2 diabetes mellitus

  • At least 2 times a fasting glucose > 7,0 mmol/L
  • Or elevated non-fasting glucose >11,1 mmol/L 2 hrs after OGTT
  • Or ≥48 mmol/mol (≥6.5%)
  • Or being actively treated for previously diagnosed type 2 diabetes by a health care provider

Obesity

  • (BMI) > 30
  • Or waist circumferences Caucasian: male ≥ 94 cm, female ≥ 80 cm South-Asian/Chinese: male ≥90 cm, female ≥80 cm Japanese: male ≥85 cm, female ≥90 cm

Arterial hypertension

  • Systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg
  • Or being actively treated for previously diagnosed arterial hypertension by a health care provider

Metabolic syndrome

  • Central obesity defined as waist circumference (see above), if BMI is >30 kg/m2, central obesity can be assumed and waist circumference does not need to be measured

AND any two of the following:

  • Raised triglycerides: ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid abnormality
  • Reduced HDL cholesterol: \< 40 mg/dL (1.03 mmol/L) in males, \< 50 mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid abnormality
  • Raised blood pressure (BP): systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or treatment of previously diagnosed hypertension
  • Raised fasting plasma glucose (FPG): FGP ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes (if above >5.6 mmol/L or 100 mg/dL, an oral glucose tolerance test is strongly recommended, but is not necessary to define presence of the syndrome)

Exclusion criteria

Exclusion Criteria:

  • The patient is known with , C or or any other liver condition (like hemochromatosis, sarcoidosis, Wilson's disease etc);
  • The patient is known with any other condition that may lead to liver fibrosis or cirrhosis;
  • The patient engages in (excessive) alcohol use: > 3 units/day in males [30 grams/day] and > 2 units/day in females [20 grams/day];
  • The patient has a history or evidence of any other condition or planned or expected procedure that in the opinion of the Investigator, may compromise the patient's safety or ability to be included in this study;
  • The patient is an employee or contractor of the facility that is conducting the study or is a family member of the Investigator, sub-Investigator, or any Sponsor personnel;
  • The patient is not able to understand the details of the protocol and/or is not able to provide written ;
  • The patient is pregnant or breastfeeding.
  • The patient underwent bariatric surgery in the last 12 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Prevalence of liver steatosis and MASLD estimated by FibroScan CAP in patients at risk

    Steatosis grade deduced from controlled attenuation parameter (CAP) measurement with Fibroscan

    Time frame: Baseline

  2. Prevalence of liver fibrosis estimated by FibroScan LSM in patients at risk

    Fibrosis stage deduced from liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE) measurement with Fibroscan

    Time frame: Baseline

  3. Prevalence of at-risk MASH estimated by FAST score in patients at risk

    At-risk MASH deduced from FAST score

    Time frame: Baseline

  4. *Subset of patients: prevalence of MASH in patients at risk

    MASH diagnosis confirmed by histology (NAS/SAF criteria) upon liver biopsy; only in patients with \>12 kPa at 1st FibroScan or \>=8 kPa at 2nd FibroScan

    Time frame: 16 or 30 weeks

  5. Comparison of the prevalence of MASLD, liver fibrosis and (at-risk) MASH between the participating countries

    Prevalence (see outcome 1-4) stratified per country

    Time frame: Baseline (1-3) to 16/30 weeks for biopsy-confirmed MASH (4)

  6. Evaluate added value of a 2-step pathway as compared to FibroScan only for detection of high-risk patients

    Number of patients at risk identified by FIB-4 compared to numbers found using LSM by VCTE with FibroScan measurements, and numbers found in combination

    Time frame: Baseline

Secondary outcomes

  1. Build diagnostic model to identify MASH patients in a high-risk population

    Possible model parameters are all baseline clinical characteristics reported in the eCRF

    Time frame: Baseline

  2. Genotypes related to MASH in different European countries: Exploratory

    Genomic (GWAS) and proteomic analysis on collected blood samples

    Time frame: Baseline

  3. (Non-invasive) metabolite biomarkers identifying MASH in patients at risk: Exploratory

    Mass-spectrometry (MS) based metabolomic and lipidomic analyses on collected blood and samples, both targeted and untargeted approaches.

    Time frame: Baseline

  4. Prevalence of co-morbidities and associated therapies (especially for CVD) in patients with MASH compared to those without, in high-risk patient populations

    Prevalence of comorbidities, medication use, medical history

    Time frame: Baseline

  5. Identify prognostic factors/biomarkers for complications in patients with MASLD and MASH by 5 years follow up

    Disease progression and liver-related and non-liver related complications

    Time frame: Throughout follow-up (at 3 and 5 years)

  6. Patient Reported Outcomes: Dietary habits and lifestyle

    14 item Mediterranean Diet Score; lifestyle surveys

    Time frame: Baseline + throughout follow-up (at 3 and 5 years)

  7. *Subset of patients: Second FibroScan examination

    CAP and LSM by VCTE at 2nd FibroScan examination

    Time frame: 14 weeks

  8. Longitudinal changes in liver assessments

    Repeated CAP, LSM by VCTE and FAST measurements over time

    Time frame: Baseline, 14 weeks + throughout follow-up (at 3 and 5 years)

07

Study locations

6 of 13 sites recruiting
  • Hôpital Erasme, Cliniques Universitaires De Bruxelles
    Brussels, Vlaams-brabant B-1070, Belgium
    Recruiting
  • Antwerp University Hospital
    Antwerp, B-2650, Belgium
    Active, not recruiting

    Not enrolling at this site.

  • 4th internal clinic General University Hospital
    Prague, Bohemia 128 08, Czechia
    Not yet recruiting
  • Hôpital de la Pitié Salpêtrière
    Paris, Il-de-France 75013, France
    Not yet recruiting
  • Universitätsmedizin Mainz
    Mainz, Rhineland-Palatinate 55131, Germany
    Recruiting
  • Universitätsklinikum des Saarlandes
    Homburg, Saarland 66421, Germany
    Not yet recruiting
  • Harokopio University of Athens
    Athens, 17676, Greece
    Not yet recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG), Università Cattolica del Sacro Cuore (UCSC)
    Rome, Lazio 00168, Italy
    Not yet recruiting
  • Amsterdam UMC
    Amsterdam, Zuid-holland 1105 AZ, Netherlands
    Recruiting
  • Franciscus Gasthuis & Vlietland
    Rotterdam, Zuid-Holland 3045 PM, Netherlands
    Recruiting
  • ULSSM - Unidade Local de Saúde Santa Maria, E.P.E
    Lisbon, 1649-028, Portugal
    Recruiting
  • Sacele Municipal Hospital
    Sacele, Brasov 505600, Romania
    Not yet recruiting
  • Hospital Universitario Virgen del Rocío
    Seville, 41013, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Mar 2031, 93 months after the start.

Of 247 observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 93 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Dec 15, 2022
StartActual
Jun 30, 2023
Primary completionEst.
Mar 31, 2031
CompletionEst.
Mar 31, 2031
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05651724
Lead sponsor
Julius Clinical
Collaborators
UMC Utrecht, Echosens, MIMETAS BV, Nordic Bioscience A/S, Elevate BV, Leiden University, Amsterdam University Medical Center, Andaluz Health Service, National Research Council, Institute of Clinical Physiology, Italy, Leiden University Medical Center, Université Libre de Bruxelles, University Hospital, Antwerp, Catholic University of the Sacred Heart, Medical Education Research And Innovation Center S.R.L., EUROPEAN LIVER PATIENTS ASSOCIATION, Harokopio University, General University Hospital, Prague, Novo Nordisk A/S, Maastricht University, Mercodia Aktiebolag, EXIT071 BV, European Atherosclerosis Society, MetaDeq Limited, Associação para Investigação e Desenvolvimento da Faculdade de Medicina, Institute of Cardiometabolism and Nutrition, France, University Hospital, Saarland, Roche Pharma AG, Inventiva Pharma, Biocellvia, Franciscus Gasthuis & Vlietland (Hospital)
Responsible party
Sponsor
First posted
Dec 15, 2022
Start date
Jun 30, 2023
Primary completion
Mar 31, 2031 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Aug 1, 2024

Study contacts

de Jong
Contact
griponmash@juliusclinical.com
+31628259968
Manuel Castro Cabezas, MD/PhD
principal investigator · Sint Franciscus Gasthuis
Diederick E. Grobbee, MD/PhD/FESC
principal investigator · UMC Utrecht
Oscar H. Franco, MD/PhD/FESC/FFPH
study chair · UMC Utrecht

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion